| 冯凌飞,贺曾.赫赛汀联合多西他赛对人表皮生长因子受体?2阳性转移性乳腺癌的临床疗效[J].安徽医药,2020,24(10):2095-2098. |
| 赫赛汀联合多西他赛对人表皮生长因子受体?2阳性转移性乳腺癌的临床疗效 |
| Clinical efficacy of Herceptin combined with docetaxel on human epidermal growth factor receptor?2 positive metastatic breast cancer |
| |
| DOI：10.3969/j.issn.1009?6469.2020.10.045 |
| 中文关键词: 乳腺肿瘤 /药物疗法 受体，雌激素 抗体，单克隆 曲妥珠单抗 赫赛汀 多西他赛 人表皮生长因子受体 ?2 阳性转移性乳腺癌 临床疗效 |
| 英文关键词: Breast neoplasms / drug therapy Receptors,estrogen Antibodies,monoclonal Trastuzumab Herceptin Docetaxel Human epidermal growth factor receptor Positive metastatic breast cancer Clinical efficacy |
| 基金项目: |
|
| 摘要点击次数: 2044 |
| 全文下载次数: 783 |
| 中文摘要: |
| 目的研究赫赛汀联合多西他赛对人表皮生长因子受体 ?2(HER?2)阳性转移性乳腺癌(PMBC)的临床疗效。方法选择 2016年 2月至 2018年 3月来开封市中心医院乳腺甲状腺科就诊的 PMBC病人 80例，根据随机数字表法分为两组，对照组 40例采用常规治疗结合赫赛汀，研究组 40例采用在对照组的基础上联合多西他赛。比较两组病人高迁移率族蛋白 I?C(HMGI?C)基因和分子标志物的表达水平与血清 C反应蛋白(CRP)、白细胞介素 ?6(IL?6)水平、并发症与随访结果情况。结研究组总有效率为 75.00%，明显优于对照组的 52.50%(P＜0.05)；研究组病人 HMGI?C基因的表达阳性率、平均标签指数(果LI)值与 p53阳性率均明显低于对照组(P＜0.05)，而雌激素受体阴性率均明显高于对照组(P＜0.05)；治疗后，两组病人 CRP水平明显降低， IL?6水平明显上升(P＜0.05)，但研究组病人 CRP、IL?2水平均明显优于对照组(P＜0.05)；研究组、对照组病人总并发症发生率分别为 10.00%、5.00%(χ2=0.721，P=0.396)，随访期间，研究组、对照组病人死亡率为 40%、55%(χ2= 1.782，P=0.182)。结论采用赫赛汀联合多西他赛可以明显提高 HER?2 PMBC病人的临床疗效，抑制癌细胞发展，降低并发症发生率，改善病人预后。 |
| 英文摘要: |
| Objective To study the clinical efficacy of Herceptin combined with docetaxel on human epidermal growth factor recep? tor?2(HER2)positive metastatic breast cancer(PMBC).Methods Eighty patients with PMBC who came to the Department ofBreast and Thyroid of Kaifeng Central Hospital from February 2016 to March 2018 were selected and assigned into two groups ac?cording to the random number table method.40 patients in the control group were treated with conventional treatment combinedwith Herceptin，while 40 patients in the study group were combined with docetaxel on the basis of the control group.The expressionlevels of high mobility group protein I?C(HMGI?C)gene and molecular markers and serum C?reactive protein(CRP)，interleukin? 6(IL?6)levels，complications and follow?up results were compared between the two groups.Results The total effective rate of the study group was 75.00%，which was significantly better than 52.50% of the control group(P＜0.05).The positive rate，mean label? ing index(LI)and p53 positive rate of HMGI?C gene in the study group were significantly lower than those in the control group(P＜0.05)，while the estrogen receptor negative rate in the study group was significantly higher than that in the control group(P＜0.05).After treatment，CRP levels were significantly decreased，and IL?6 levels were significantly increased in the two groups(P＜0.05)，but the CRP and IL?2 levels in the study group were significantly better than those in the control group(P＜0.05).The total complication rate of patients in the study group and the control group was 10.00% and 5.00%，respectively(χ2=0.721，P=0.396). During the follow?up period，the mortality of the study group and the control group was 40% and 55%，respectively(χ2=1.782，P=0.182).Conclusion The combination of Herceptin and docetaxel can significantly improve the clinical efficacy of HER?2 PMBC patients，inhibit the development of cancer cells，reduce the incidence of complications，and improve the prognosis of patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
